Caregivers of younger children with fragile X syndrome (FXS), and those with lower…
Ana Pena, PhD
Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
A combination of two chemical modulators of gene activity can stably reactivate the FMR1 gene, the gene that is “switched…
Early Check, a free newborn screening program for fragile X syndrome (FXS) that recently began testing in North…
Lovastatin, a medication widely prescribed for lowering cholesterol, was recently discovered to correct brain deficits…
New interactions involving the FMRPÂ and p53 proteins were found to play an important part in…
Chemical modification of a DNA-binding protein may provide a new therapeutic target to treat fragile X syndrome (FXS), a…
A University of Virginia scientist has won the Hartwell Individual Biomedical Research Award for her work on neurodevelopmental…
The University of California at Davis’s MIND Institute is recruiting children and young…